Literature
An updated systematic review of the impact of volume of surgery and specialization in Norwood procedure.
An updated systematic review of the impact of volume of surgery and specialization in Norwood procedure.: New evidence identified. See linked sources for details.
PROSPERO CRD42022385160.
Relevance: Directly relevant systematic review examining Norwood procedure outcomes. The Norwood is the first-stage surgical treatment for HLHS (dx-hlhs), a primary diagnosis in the profile. Addresses single ventricle outcomes and surgical quality metrics central to pediatric cardiology practice.
PMID: 42337493BMC pediatrics(Journal Article) Literature
Efficacy and safety of apixaban versus warfarin in LVAD patients: A propensity-matched analysis.
Efficacy and safety of apixaban versus warfarin in LVAD patients: A propensity-matched analysis.: New evidence identified. See linked sources for details.
Although warfarin remains the standard anticoagulant for LVAD recipients, apixaban demonstrated lower rates of major adverse events in this large retrospective analysis. Further prospective and...
Relevance: Retrospective cohort study comparing anticoagulation strategies (warfarin vs apixaban) in LVAD patients. Directly addresses drug-profile warfarin (drug-warfarin) and pediatric anticoagulation research interest. However, adult population; findings are relevant to inform pediatric practice but study not conducted in pediatric patients.
PMID: 42359860Wiadomosci lekarskie (Warsaw, Poland : 1960)(Journal Article) Literature
Heart Failure Etiology and 6-Month Cardiorenal Recovery Patterns After Early In-Hospital SGLT2 Inhibitor Initiation in HFrEF: A Prospective Real-World Cohort.
Heart Failure Etiology and 6-Month Cardiorenal Recovery Patterns After Early In-Hospital SGLT2 Inhibitor Initiation in HFrEF: A Prospective Real-World Cohort.: New evidence identified. See linked sources for details.
These findings characterize etiology-related recovery within a treated cohort rather than differential SGLT2 inhibitor efficacy and should therefore be considered as hypothesis-generating.
Relevance: Prospective cohort study of SGLT2 inhibitor effects on HFrEF outcomes in adults. Related to heart failure research interest but does not directly address profile diagnoses, single ventricle physiology, or Fontan circulation. Adult-focused study with limited pediatric applicability.
PMID: 42356030Medicina (Kaunas, Lithuania)(Journal Article) Literature
Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study.
Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study.: New evidence identified. See linked sources for details.
These findings may inform target validation, drug repurposing, and personalized therapies for CKM syndrome.
Relevance: Drug-target Mendelian randomization study of glucose-lowering agents on cardiovascular-kidney-metabolic outcomes. Related to heart failure and pulmonary hypertension research interests, but primarily addresses metabolic disease management in adults; limited relevance to pediatric cardiology diagnoses.
PMID: 42328113International journal of medical sciences(Journal Article) Literature
Comparative efficacy of lipid-lowering therapies on the cardio-renal-metabolic axis in diabetic kidney disease: a Bayesian network meta-analysis addressing residual CRM risk.
Comparative efficacy of lipid-lowering therapies on the cardio-renal-metabolic axis in diabetic kidney disease: a Bayesian network meta-analysis addressing residual CRM risk.: New evidence identified. See linked sources for details.
https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420251049719.
Relevance: Bayesian network meta-analysis of lipid-lowering therapies on cardio-renal-metabolic outcomes in diabetic kidney disease. Related to heart failure and pulmonary hypertension research interests, but addresses adult diabetes management; limited applicability to pediatric cardiology diagnoses.
PMID: 42290868Frontiers in endocrinology(Journal Article)